A loopless subdomain of transferrin binding protein B can elicit a broadly cross-reactive humoral immune response targeting variants from both encapsulated and non-typeable Haemophilus influenzae
Haemophilus influenzae is a Gram-negative bacterium that causes pneumonia, otitis media, and invasive infections such as meningitis and bacteremia. A vaccine that confers protection against disease caused by H. influenzae serotype b is currently available and is highly effective, but infections caused by non-b serotypes and non-typeable strains are still prevalent and increasing, suggesting a need for a broadly cross-protective vaccine that will protect against infection by all H. influenzae strains. To address the need for broad cross-protection, this study focused on the surface lipoprotein component of the bipartite bacterial transferrin receptor, transferrin binding protein B (TbpB), which is universally present H. influenzae, irrespective of encapsulation status, and is essential for bacterial colonization and pathogenesis. To prevent vaccine escape, we assessed the sequence and structural diversity among TbpB variants derived from local and international H. influenzae isolates and observed that these sequences cluster independently of encapsulation status, suggesting that conferring protection against all H. influenzae strains regardless of capsule type or presence of a capsule using a TbpB-based vaccine is feasible. In addition, our diversity analysis also revealed that the C-terminal lobe (C-lobe) of TbpB contains several large, highly variable loops. After immunizing mice with a trivalent vaccine consisting of a representative set of TbpB variants, we found that the resulting antiserum demonstrated modest cross-reactivity against heterologous TbpB variants. However, immunizing with a loopless C-lobe (LCL) that lacks the large, highly variable loops we had identified elicited broad cross-reactivity against a panel of intact TbpB variants. This suggests that while the intact TbpB may only generate a moderately cross-reactive antibody response, a vaccine consisting of a single LCL may be able to elicit a sufficiently cross-reactive humoral response against diverse TbpB variants, and in turn, confer broad cross-protection targeting both encapsulated and non-typeable H. influenzae.